

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<i>Application Number</i>	10/553,722
				<i>Filing Date</i>	07/10/2006
				<i>First Named Inventor</i>	Rosanne M. Crooke
				<i>Art Unit</i>	1635
				<i>Examiner Name</i>	Terra C. Gibbs
(Use as many sheets as necessary)					
Sheet	1	of	4	Attorney Docket Number	BIOL0004USA

## U.S. PATENT DOCUMENTS

---

**FOREIGN PATENT DOCUMENTS**

---

Examiner Signature	/Terra Cotta Gibbs/	Date Considered	10/25/2007
-----------------------	---------------------	--------------------	------------

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant." Applicant's unique citation designation number (optional). See Kind Codes of USPTO Patent Documents at [www.uspto.gov/or MPEP 901.04](http://www.uspto.gov/or MPEP 901.04). Enter Office that issued the document, by the two-letter code (WIPO) Standard ST 3.4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon individual needs. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of

4

## Complete if Known

Application Number	10/553,722
Filing Date	07/10/2006
First Named Inventor	Rosanne M. Crooke
Art Unit	1635
Examiner Name	Terra C. Gibbs
Attorney Docket Number	BIOL0004USA

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.); date, page(s), volume-issue numbers), publisher, city and/or country where published.	T <sup>2</sup>
/TCG/	AG	AGRAWAL, S. et al., "Antisense therapeutics: is it as simple as complementary base recognition?" <i>Mol. Med. Today</i> (2000) 6:72-81.	
	AH	BRAASCH, D. A. et al., "Novel Antisense and Peptide Nucleic Acid Strategies for Controlling Gene Expression," <i>Biochem.</i> (2002) 41(14):4503-4510.	
	AI	BRANCH, A. D., "A good antisense molecule is hard to find," <i>TIBS</i> (1998) 23:45-50.	
	AJ	CROOKE, S. T., "Progress in Antisense Technology," <i>Ann. Rev. Med.</i> (2004) 55:61-95.	
	AK	DAMMERMAN, M. et al., "An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3' untranslated region polymorphisms," <i>Proc. Natl. Acad. Sci. USA</i> (1993) 90:4562-4566.	
	AL	DE SILVA, H. V. et al., "Overexpression of Human Apolipoprotein C-III in Transgenic Mice Results in an Accumulation of Apolipoprotein B48 Remnants That Is Corrected by Excess Apolipoprotein E," <i>J. Biol. Chem.</i> (1994) 269(3):2324-2335.	
	AM	GEWIRTZ, A. M. et al., "Facilitating oligonucleotide delivery: Helping antisense deliver on its promise." <i>Proc. Natl. Acad. Sci. USA</i> (1996) 93:3161-3163.	
	AN	HERTZ, R. et al., "Mode of Action of Peroxisome Proliferators as Hypolipidemic Drugs," <i>J. Biol. Chem.</i> (1995) 270(22):13470-13475.	
	AO	ITO, Y. et al., "Hypertriglyceridemia as a Result of Human Apo CIII Gene Expression in Transgenic Mice," <i>Science</i> (1990) 249:790-793.	
	AP	JEN, K.-Y. et al., "Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies," <i>Stem Cells</i> (2000) 18:307-319.	
	AQ	KARATHANASIS, S. K., "Apolipoprotein multigene family: Tandem organization of human apolipoprotein AI, CIII, and AIIV genes," <i>Proc. Natl. Acad. Sci. USA</i> (1985) 82:6374-6378.	
↓	AR	KARDASSIS, D. et al., "SMAD Proteins Transactivate the Human ApoCIII Promoter by Interacting Physically and Functionally with Hepatocyte Nuclear Factor 3," <i>J. Biol. Chem.</i> (2000) 275(52):41405-41414.	
/TCG/	AS	KARDASSIS, D. et al., "Direct Physical Interactions between HNF-4 and Sp1 Mediate Synergistic Transactivation of the Apolipoprotein CIII Promoter," <i>Biochem.</i> (2002) 41(4):1217-1228.	

Examiner Signature	/Terra Cotta Gibbs/	Date Considered	10/25/2007
--------------------	---------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

3

of

4

## Complete if Known

Application Number	10/553,722
Filing Date	07/10/2006
First Named Inventor	Rosanne M. Crooke
Art Unit	1635
Examiner Name	Terra C. Gibbs
Attorney Docket Number	BIOL0004USA

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue numbers), publisher, city and/or country where published.	T <sup>2</sup>
/TCG/	AT	LEVY-WILSON, B. et al., "Isolation and DNA Sequence of Full-Length cDNA for Human Preapoprotein CIII," <i>DNA</i> (1984) 3(5):359-364.	
	AU	LI, W. W. et al., "Common Genetic Variation in the Promoter of the Human apo CIII Gene Abolishes Regulation by Insulin and May Contribute to Hypertriglyceridemia," <i>J. Clin. Invest.</i> (1995) 96:2601-2605.	
	AV	MAEDA, H. et al., "Molecular cloning of a human apoC-III variant: Thr 74 → Ala 74 mutation prevents O-glycosylation," <i>J. Lipid Res.</i> (1987) 28:1405-1409.	
	AW	MAEDA, N. et al., "Targeted Disruption of the Apolipoprotein C-III Gene in Mice Results in Hypotriglyceridemia and Protection from Postprandial Hypertriglyceridemia," <i>J. Biol. Chem.</i> (1994) 269(38):23610-23616.	
	AX	OGAMI, K. et al., "Purification and Characterization of a Heat Stable Nuclear Factor CIIβ Involved in the Regulation of the Human ApoC-III Gene," <i>J. Biol. Chem.</i> (1991) 266(15):9640-9646.	
	AY	OLIVIERI, O. et al., "ApoC-III gene polymorphisms and risk of coronary artery disease," <i>J. Lipid Res.</i> (2002) 43:1450-1457.	
	AZ	OLIVIERI, O. et al., "Apolipoprotein C-III, n-3 Polyunsaturated Fatty Acids, and "Insulin-Resistant" T-455C APOC3 Gene Polymorphism in Heart Disease Patients: Example of Gene-Diet Interaction," <i>Clin. Chem.</i> (2005) 51(2):360-367.	
	BA	OPALINSKA, J. B. et al., "Nucleic-Acid Therapeutics: Basic Principles and Recent Applications," <i>Nature Rev. Drug Discov.</i> (2002) 1:503-514.	
	BB	PROTTER, A. A. et al., "Isolation and Sequence Analysis of the Human Apolipoprotein CIII Gene and the Intergenic Region between the Apo AI and Apo CIII Genes," <i>DNA</i> (1984) 3(6):449-456.	
	BC	RASPÉ, E. et al., "Identification of Rev-erba as a physiological repressor of apoC-III gene transcription," <i>J. Lipid Res.</i> (2002) 43:2172-2179.	
↓	BD	SCHOIJANS, K. et al., "3-Hydroxy-3-methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C-III and lipoprotein lipase," <i>FEBS Lett.</i> (1999) 452:160-164.	
/TCG/	BE	SENIOR, K. "Antisense inhibitor provides new treatment approach for hypercholesterolemia," <i>DDT</i> (2002) 7(16):840-841.	

Examiner Signature	/Terra Cotta Gibbs/	Date Considered	10/25/2007
--------------------	---------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<i>Application Number</i>	10/553,722
				<i>Filing Date</i>	07/10/2006
				<i>First Named Inventor</i>	Rosanne M. Crooke
				<i>Art Unit</i>	1635
(Use as many sheets as necessary)				<i>Examiner Name</i>	Terra C. Gibbs
Sheet	4	of	4	<i>Attorney Docket Number</i>	BIOL0004USA

Examiner Signature	/Terra Cotta Gibbs/	Date Considered	10/25/2007
-----------------------	---------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**